Entera Bio secures $10M to advance osteoporosis drug trials and R&D
Entera Bio Ltd. has secured a $10 million private placement to fund its drug development programmes. The company, listed on Nasdaq as ENTX, will issue nearly 7.83 million units at $1.2775 each. Investors include funds managed by BVF Partners L.P., with the deal set to close by early April 2026.
The funds will support a phase 3 study of EB613, a treatment for osteoporosis in postmenopausal women, alongside general corporate expenses.
The private placement involves 7,827,789 units, each consisting of one ordinary share and a five-year warrant. The warrants will be exercisable from six months after the closing date, expiring five years later. If fully exercised, they could bring in an extra $14.5 million, pushing total potential proceeds to $24.5 million.
The transaction is expected to finalise on or around April 2, 2026, pending standard closing conditions. The securities offered are not registered under the US Securities Act and cannot be sold in the US without registration or an exemption. Beyond the phase 3 trial for EB613, Entera is advancing a preclinical programme for EB612 in partnership with OPKO Health. The company plans to submit an Investigational New Drug (IND) application for EB612 by late 2026.
The funds will primarily back Entera's phase 3 osteoporosis study and broader corporate operations. With potential additional proceeds from warrant exercises, the company's total funding could reach $24.5 million. The deal marks a step forward in its clinical development pipeline.
